Scans reveal hidden body changes in lung patients
NCT ID NCT07332117
Summary
This study aims to understand how anti-fibrotic medications for lung fibrosis affect patients' body composition—specifically fat and muscle—which regular weight checks might miss. Researchers will use quick, non-invasive scans (bioimpedance analysis and muscle ultrasound) on 30 patients before and 4 months after starting treatment. The goal is to see if these tools can effectively track body changes that may result from medication side effects like nausea and loss of appetite.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Brompton Hospital
RECRUITINGLondon, SW36NP, United Kingdom
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.